APRIL 2023LIFE SCIENCES REVIEW6Immunotherapy represents a significant breakthrough in cancer treatment, offering immense promise as both a complementary approach to traditional therapies and as a cornerstone for future treatments. With its tremendous therapeutic potential, cancer immunotherapy is poised to become a standard part of cancer treatment and has already demonstrated remarkable clinical efficacy in treating cancer patients.In fact, the worldwide cancer immunotherapy market is anticipated to reach a value of $167.5 billion by 2027, exhibiting a CAGR of 9.10 percent during 2022-2027, driven by technological advancements in clinical therapies, extensive research and development (R&D) activities, and the introduction of advanced variants with enhanced efficacy and effectiveness of treatment.Among many trends in the industry, CAR-T cell therapy is a significant advancement in cancer immunotherapy, representing a breakthrough in the field. This treatment approach has already received approval from the Food and Drug Administration (FDA) to treat blood cancers, such as leukemia and lymphoma, and has demonstrated impressive results in clinical trials. CAR-T cell therapy also holds immense potential for the treatment of solid tumors, which are more difficult to treat with traditional cancer therapies. To highlight some of the recent trends in cancer immunotherapy as well as what's next for this promising field, Life Sciences Review illustrates domain leaders are viewing the next great leaps in cancer treatment. This edition features articles from James Riddle, VP of Research Services and Strategic Consulting at Advarra; Dr. Kim M. Bonner, Executive Director of Clinical Development at Syneos Health; and James Holland, Associate Scientific Director and Kindiya Geghman, Vice President, Medical & Scientific Services at Ashfield MedComms, an Inizio Company.In this edition of Life Sciences Review, we also bring to you the story of some of the top cancer immunotherapy solution providers that have been instrumental in transforming cancer outcomes and providing newfound hope to patients. In the list, Cellex Cell Professionals, a group of companies that specialises in the manufacturing of cell and gene therapy products, is leading the way with its state-of-the-art facilities and a team of experts. Equally commendable is T-CURX, a Biotech company, a spin-off from the University Clinics Würzburg, Germany, developing the best-in-class personalised immunotherapies based on CAR-T cells.Through the following pages, we aim to shine a light on the innovative trends and latest developments that showcase a brand-new era of cancer immunotherapy. We would like to know your thoughts.EDITORIALCAR-T Cell Therapy: The Next Breakthrough in Cancer ImmunotherapyCopyright © 2023 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.Email:sales@lifesciencesreview.comeditor@lifesciencesreview.commarketing@lifesciencesreview.com April - 03 - 2023, Vol 04, Issue - 08 (ISSN 2831-8331) Published by ValleyMedia, Inc.To subscribe to Life Sciences ReviewVisit www.lifesciencesreview.com Editorial StaffAaron PierceCarolynn WaltersShirley FaithRussell ThomasVisualizersRonald DonovanDisclaimer: *Some of the Insights are based on our interviews with CIOs and CXOsJeremy WilliamsManaging Editoreditor@lifesciencesreview.comManaging EditorJeremy WilliamsHenry SmithClara Matthew
< Page 5 | Page 7 >